Study guide

23.2 Hypertension & Diabetes in Pregnancy: Classification, Preeclampsia Pathogenesis and Prevention, Severe Features, Eclampsia & HELLP, Magnesium Sulfate, Gestational and Pregestational Diabetes

Philippine Physician Licensure Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: PLE Structure, Eligibility & Study Strategy

1.1 PLE Format, 2026 Schedule & the Statutory Passing Rule 1.2 Eligibility, Internship, PRC Filing & Test-Day Rules 1.3 Reading the 2025 Tables of Specifications & Building a Study Plan

2 Chapter 2: Physiology I: Cells, Blood, Nerve & Muscle

2.1 Homeostasis, Cell Function, Membrane Transport & Resting Potential 2.2 Blood Cells, Immunity, Hemostasis, Fibrinolysis & Blood Distribution 2.3 Action Potentials, Conduction, the Neuromuscular Junction & Muscle Contraction

3 Chapter 3: Physiology II: Cardiovascular & Respiratory Systems

3.1 Cardiac Electrophysiology, the Cardiac Cycle & the Heart as a Pump 3.2 Circulation: Resistance, Venous Return, Coronary Flow, Microcirculation & Fetal Circulation 3.3 Respiratory Mechanics, Gas Exchange, Gas Transport, Control of Breathing & Extreme Environments

4 Chapter 4: Physiology III: Gastrointestinal, Endocrine, Renal & Reproductive Systems

4.1 Gastrointestinal Physiology: Secretion, Motility, Digestion & Absorption 4.2 Endocrine Physiology: Hormone Chemistry, Axes, Calcium & Fuel Regulation 4.3 Renal Physiology, Body Fluid Balance & Acid-Base Regulation 4.4 Reproductive Physiology: Sexual Differentiation, Spermatogenesis, the Menstrual Cycle, Parturition & Lactation

5 Chapter 5: Physiology IV: Neurophysiology & Special Senses

5.1 Sensory Receptors, Somatic Sensation, Spinal Reflexes & Motor Control 5.2 Higher Brain Functions, Sleep, the Autonomic Nervous System, Cerebral Blood Flow & the Special Senses

6 Chapter 6: Legal Medicine I: Medicolegal Examination, Identification & Death

6.1 The Medicolegal Examination, Physical Evidence & the Crime Scene 6.2 Identification of the Living, the Dead & Skeletal Remains 6.3 Thanatology: Death, Brain Death, Postmortem Changes & Time of Death

7 Chapter 7: Legal Medicine II: Injuries, Sexual Crimes, Reproduction, Mental State & Poisoning

7.1 Physical Injuries: Revised Penal Code Classes, Wounds, Gunshot Injuries, Asphyxia & Burns 7.2 Sexual Crimes, Violence Against Women & Child Abuse 7.3 Medicolegal Aspects of Pregnancy, Delivery, Abortion, Infanticide, Paternity & Marriage 7.4 Disturbance of Mentality: Insanity, Intoxication, Capacity & the Mental Health Act 7.5 Forensic Toxicology & Poisoning: Diagnosis, Evidence, Antidotes & Philippine Laws

8 Chapter 8: Legal Medicine III: Reports, Regulation, Liability & Ethics

8.1 The Medicolegal Report, the Death Certificate, Autopsy Rules & Communicating with Relatives 8.2 Licensure & Regulation of Medical Practice: RA 2382, the Board of Medicine, PRC & Prescribing Laws 8.3 Medical Malpractice: Civil, Criminal & Administrative Liability and Key Philippine Doctrines 8.4 Physician Relationships Under the PMA Code of Ethics: Patients, Colleagues, Allied Health, Students, Industry, HMOs, Hospitals & PhilHealth 8.5 Bioethical Principles, Informed Consent, Confidentiality, End-of-Life & Research Ethics

9 Chapter 9: Pathology I: Cell Injury, Inflammation & Hemodynamics

9.1 Cell Injury, Adaptation, Necrosis, Apoptosis, Accumulations & Calcification 9.2 Acute & Chronic Inflammation, Granulomas, Systemic Effects & Tissue Repair 9.3 Hemodynamic Disorders: Edema, Hemorrhage, Thrombosis, Embolism, Infarction, DIC & Shock

10 Chapter 10: Pathology II: Genetics, Neoplasia, Immunity, Environment & Infection

10.1 Genetic Disorders & Neoplasia: Mendelian, Chromosomal, Non-Classic Inheritance, Tumor Biology & Markers 10.2 Immunopathology: Hypersensitivity, Autoimmunity, Immunodeficiency & Transplant Rejection 10.3 Environmental & Nutritional Pathology: Air Pollution, Tobacco, Metals, Occupational Lung Disease & Deficiency States 10.4 Pathology of Infectious Diseases: Transmission, Tissue Reaction Patterns & Diagnostic Morphology

11 Chapter 11: Pathology III: Gastrointestinal, Cardiovascular & Respiratory Pathology

11.1 Gastrointestinal, Hepatic, Biliary & Pancreatic Pathology 11.2 Cardiovascular & Collagen Pathology: Heart Failure, Congenital, Ischemic, Hypertensive, Valvular, Pericardial & Myocardial Disease 11.3 Respiratory Pathology: Atelectasis, Edema, ARDS, Obstructive & Restrictive Disease, Vascular Disease, Infections, Tumors & Pleura

12 Chapter 12: Pathology IV: Hematopoietic, Genitourinary, Endocrine & Nervous System Pathology

12.1 Hematopoietic Pathology: Anemias, Polycythemia, Bleeding Disorders, DIC & Lymphoid and Myeloid Neoplasms 12.2 Genitourinary Pathology: Glomerular, Tubulointerstitial, Vascular & Cystic Kidney Disease, Renal Tumors, Obstruction & Genital Disorders 12.3 Endocrine Pathology: Pancreas, Adrenal, Parathyroid, Thyroid & Pituitary Disorders 12.4 Nervous System Pathology: Cerebrovascular Disease, Edema & Herniation, Infections, Degenerative & Demyelinating Disease, Tumors

13 Chapter 13: Biochemistry I: Carbohydrate, Protein, Genetic & Energy Biochemistry

13.1 Carbohydrate Chemistry, Digestion, Glycolysis, Pyruvate Dehydrogenase & the Pentose Phosphate Pathway 13.2 Gluconeogenesis, Glycogen, Lipogenesis, Ketogenesis & Hormonal Control of Fuel Metabolism 13.3 Protein Digestion, Amino Acid Catabolism, the Urea Cycle, Heme Synthesis, Porphyrias & Bilirubin Metabolism 13.4 Amino Acids & Proteins: Structure, Properties, Separation, Specialized Products, Collagen & Protein Misfolding in Alzheimer Disease 13.5 Molecular Genetics & Enzymes: Replication, Repair, Gene Expression, Molecular Techniques, Lysosomal Storage Diseases & Enzyme Kinetics 13.6 Bioenergetics, the Citric Acid Cycle, Oxidative Phosphorylation, Muscle Energetics & Nucleotide Metabolism

14 Chapter 14: Biochemistry II: Respiratory, Nutritional, Immunologic & Cardiovascular Biochemistry

14.1 Respiratory Biochemistry: Hemoglobin, Oxygen Binding, Hemoglobinopathies, Thalassemias, Methemoglobin, Buffers & Acid-Base Balance 14.2 Nutrition Biochemistry: Dietary Standards (RENI to PDRI 2015), Food Guides, Protein Quality, Energy Expenditure, Breast Milk, Vitamins, Minerals & Blood Components 14.3 Immunology: Innate & Adaptive Immunity, the Immune Response, Antibodies, Complement, Cytokines & MHC 14.4 Cardiovascular Biochemistry: Cholesterol, Lipoproteins, Dyslipidemias, Atherogenesis, Myocardial Energetics, Biomarkers & Heart Failure

15 Chapter 15: Anatomy I: Thorax, Abdomen, Pelvis & Back

15.1 Thorax: Thoracic Wall, Breast, Pleura & Lungs, Mediastinum, Heart & Great Vessels 15.2 Abdomen: Abdominal Wall & Inguinal Region, Peritoneum, Viscera, Diaphragm & Posterior Abdominal Wall 15.3 Pelvis & Perineum: Bony Pelvis, Pelvic Floor, Pelvic Viscera, Vessels & Nerves, Perineal Pouches & the Anal Canal 15.4 Back & Spinal Column: Vertebrae, Curvatures, Joints, Back Muscles, Spinal Cord, Meninges & Cord Syndromes

16 Chapter 16: Anatomy II: Upper Limb, Lower Limb & Skin

16.1 Upper Limb: Bones, Superficial Veins, Shoulder Muscles, Axilla & Brachial Plexus, Arm, Cubital Fossa, Forearm, Hand & Joints 16.2 Lower Limb: Bones, Venous & Lymphatic Drainage, Thigh, Gluteal Region, Popliteal Fossa, Leg Compartments, Foot, Joints & Gait 16.3 Skin & Appendages: Epidermis, Junctions, Dermis, Subcutaneous Tissue, Fascia, Nerves, Vessels, Lymphatics, Hair, Nails & Glands

17 Chapter 17: Anatomy III: Head, Neck & Histology

17.1 Head I: Skull & Cranial Foramina, Scalp, Face & Parotid, Orbit, Temporal & Infratemporal Fossae, TMJ, Oral Region, Nose & Ear 17.2 Head II: Meninges & Dural Venous Sinuses, Brain Regions & Ventricles, Blood Supply, Cranial Nerves, Pituitary & Pineal, Brainstem Syndromes 17.3 Neck: Cervical Vertebrae & Hyoid, Fascial Layers, Superficial Muscles, Triangles, Root of the Neck, Visceral Layers & Lymphatics 17.4 Histology: Cells, Epithelium & Glands, Connective Tissue & Fat, Cartilage & Bone, Blood & Hematopoiesis, Muscle, Nerve, Vessels, Lymphoid Organs & Organ Histology

18 Chapter 18: Microbiology I: Foundations, Respiratory & Cardiovascular Infections

18.1 Microbiology Foundations: The Organ-System TOS, Specimens & Stains, Gram-Positive and Gram-Negative Bacteria 18.2 Respiratory Infections: Tonsillitis, Sinusitis & Mastoiditis, Bronchitis, Community-Acquired & Severe Pneumonia, Bronchiectasis and Paragonimiasis 18.3 Tuberculosis, Leprosy & Nontuberculous Mycobacteria: Pathogenesis, Diagnosis, NTP Regimens & Prevention 18.4 Cardiovascular Infections: Infective Endocarditis, Rheumatic Fever & Rheumatic Heart Disease, Myocarditis, Pericarditis and Septic Thrombophlebitis

19 Chapter 19: Microbiology II: Gastrointestinal & Nervous System Infections

19.1 Gastrointestinal Infections I: Gastroenteritis & Enterocolitis, Cholera, Typhoid & Salmonellosis, Shigellosis, Food Poisoning and Viral Hepatitis 19.2 Gastrointestinal Infections II: Amebiasis, Giardiasis & Cryptosporidiosis, Soil-Transmitted Helminths, Pinworm, Capillariasis and Tapeworms 19.3 Nervous System Infections: Meningitis & CSF Patterns, Encephalitis, Rabies and DOH PEP, Spinal Cord Infections, Tetanus & Botulism, Paralytic Shellfish Poisoning

20 Chapter 20: Microbiology III: Genitourinary, Reproductive, Blood & Skin Infections

20.1 Genitourinary Infections: Cystitis & Pyelonephritis, Urine Diagnostics, Urethritis, Balanoposthitis, Pelvic Inflammatory Disease and Genital Ulcers 20.2 Reproductive Tract Infections & STIs: Syphilis, Genital & Neonatal Herpes, HPV, Molluscum, CMV, Trichomoniasis & Vaginitis, Cervicitis, Prostatitis and Orchitis 20.3 Hematopoietic & Lymphatic Infections: Dengue and Other Hemorrhagic Fevers, Malaria, Lymphatic Filariasis, Lymphogranuloma Venereum and Epstein-Barr Virus 20.4 Integumentary Infections: Viral Exanthems (Measles, Mumps, Rubella, Varicella, Smallpox & Mpox, Fifth Disease), Herpesviruses, Fungal Skin Infections and Tick-Borne Diseases

21 Chapter 21: Microbiology IV: Musculoskeletal & Multisystemic Infections

21.1 Musculoskeletal & Soft-Tissue Infections: Osteomyelitis, Septic & Reactive Arthritis, Pyomyositis & Gas Gangrene, Cellulitis, Necrotizing Fasciitis and Bite Wounds 21.2 Multisystemic Infections I: Septicemia, Septicopyemia & Septic Shock, Leptospirosis and Schistosomiasis japonica 21.3 Multisystemic Infections II: HIV/AIDS Virology, the Philippine Epidemic & RA 11166, Diagnosis (rHIVda), ART, Prevention and Opportunistic Infections including Toxoplasmosis

22 Chapter 22: Obstetrics I: Prenatal Care, Labor & Obstetric Bleeding

22.1 Prenatal Care: Diagnosis of Pregnancy, Maternal Physiology, Dating, Nutrition & Supplements, Screening Tests and the DOH Antenatal Package 22.2 Labor & Parturition: Signs of Labor, Pelvis and Passenger, Stages and Cardinal Movements, Partograph, Fetal Monitoring, Dystocia, Shoulder Dystocia, Operative Delivery, Preterm Labor, PROM and Adolescent Pregnancy 22.3 Early Pregnancy Risks & Bleeding: Hyperemesis, Spontaneous Abortion, Recurrent Loss & Cervical Insufficiency, Ectopic Pregnancy, Hydatidiform Mole & Gestational Trophoblastic Neoplasia 22.4 Hemorrhagic Complications of Pregnancy: Placenta Previa, Abruption, Vasa Previa, Placenta Accreta Spectrum, Uterine Rupture, Third-Stage Management and Postpartum Hemorrhage

23 Chapter 23: Obstetrics II: Fetal, Hypertensive, Medical, Infectious & Postpartum Problems

23.1 Fetal Complications: Malpresentation & Breech, Macrosomia, Fetal Growth Restriction, Amniotic Fluid Disorders, Antepartum Surveillance, Rh Alloimmunization, Multiple Gestation and Post-Term Pregnancy 23.2 Hypertension & Diabetes in Pregnancy: Classification, Preeclampsia Pathogenesis and Prevention, Severe Features, Eclampsia & HELLP, Magnesium Sulfate, Gestational and Pregestational Diabetes 23.3 Medical & Surgical Disorders in Pregnancy: Drug Pharmacokinetics, Epilepsy, Thyroid, Heart Disease, SLE & APS, Asthma, Liver Disorders, Anemia, Dermatoses, Appendicitis, Gallstones, Stones and Trauma 23.4 Perinatal Infections: Triple Elimination (HIV, Syphilis, Hepatitis B), Group B Streptococcus, Chorioamnionitis, Gonorrhea & Chlamydia, Condyloma, Herpes and the TORCH Infections 23.5 Postpartum Care & Complications: Normal Puerperium, Postnatal Visits, Breastfeeding, Puerperal Fever and Infection, Mastitis, Late Hemorrhage, Mood Disorders, VTE and Postpartum Contraception

24 Chapter 24: Gynecology I: Benign Disorders, Infections & Contraception

24.1 Benign Lower Genital Tract Disorders & Pelvic Floor: Vulvar Dermatoses, Bartholin Cysts, Vaginal and Cervical Lesions, Premalignant Lesions, Pelvic Organ Prolapse, Urinary Incontinence and Fistula 24.2 Benign Upper Genital Tract Disorders: Leiomyoma, Adenomyosis & Endometriosis, Endometrial Polyps and Hyperplasia, Functional Cysts and Benign Ovarian Tumors, Adnexal Torsion and Tubal Disease 24.3 Infections of the Female Reproductive Tract: Burden & Screening, Syndromic Management, Vaginitis and Cervicitis, Pelvic Inflammatory Disease & Tubo-Ovarian Abscess, Genital Tuberculosis and Toxic Shock 24.4 Contraception & Family Planning: The RH Law, Effectiveness, Natural and Barrier Methods, Hormonal Methods, IUDs, Permanent Methods, Emergency Contraception and the WHO Eligibility Criteria

25 Chapter 25: Gynecology II: Reproductive Endocrinology, Oncology & Special Issues

25.1 Reproductive Endocrinology & Menstrual Disorders: The Menstrual Cycle, Puberty, Abnormal Uterine Bleeding (PALM-COEIN), Amenorrhea, PCOS, Hyperprolactinemia, Dysmenorrhea, Infertility, Menopause, HRT and Osteoporosis 25.2 Gynecologic Oncology: Cervical Cancer Screening, Staging & Treatment, Endometrial Cancer and Lynch Syndrome, Ovarian Tumors and BRCA, Vulvar and Vaginal Cancer, Survival and Quality of Life 25.3 Contemporary Issues & Pediatric and Adolescent Gynecology: Violence Against Women, Sexual Assault Care, Breast Disorders, Ethics of Maternal-Fetal Conflict, and Gynecologic Problems of Children and Adolescents

26 Chapter 26: Pediatrics I: Newborn, Growth, Nutrition, Immunization & Infections

26.1 The Newborn: Normal Findings and Variants, EINC (Unang Yakap), APGAR, Neonatal Resuscitation, Routine Care & Newborn Screening, Jaundice, Respiratory Distress, Hypoglycemia and Neonatal Sepsis 26.2 Growth, Development & Nutrition: Growth Parameters, Milestones and Red Flags, Speech Delay, Autism, ADHD & Global Delay, Breastfeeding and Feeding, Micronutrient Deficiencies, Malnutrition and Obesity 26.3 Immunization: RA 10152 and the National Immunization Program Schedule, Fully Immunized Child, School-Based Immunization, Other Recommended Vaccines, Vaccine Types, Cold Chain, Contraindications and AEFI 26.4 Pediatric Infectious Diseases: Bacterial (Diphtheria to Congenital Syphilis), Childhood TB, Viral Exanthems and Infections, Dengue in Children, Pediatric HIV, Protozoal, Helminthic and Fungal Infections

27 Chapter 27: Pediatrics II: Respiratory, Cardiovascular, Neurologic & Gastrointestinal Disorders

27.1 Pediatric Respiratory Disorders: IMCI Danger Signs and Cough Assessment, URI, Tonsillitis & Peritonsillar Abscess, Croup, Epiglottitis, Foreign Body, Bronchiolitis, Pneumonia, Pleural Effusion and Complications 27.2 Pediatric Cardiovascular & Collagen Disorders: Heart Sounds and Murmurs, Acyanotic and Cyanotic Congenital Heart Disease, Eisenmenger, Hypercyanotic Spells, Heart Failure, Rheumatic Fever, Hypertension, Endocarditis, Kawasaki, SLE, JIA, Dermatomyositis and Pediatric Resuscitation 27.3 Pediatric CNS Disorders: Febrile Seizures, Epilepsy Syndromes, Status Epilepticus, Meningitis and Encephalitis in Children, Cerebral Palsy, Hydrocephalus & Neural Tube Defects, Headache and Migraine, and Brain Tumors 27.4 Pediatric GI Disorders & Poisoning: Vomiting (Pyloric Stenosis, Atresias, Malrotation, Intussusception, GERD), Diarrhea and IMCI Rehydration Plans, Abdominal Pain, Constipation & Hirschsprung, Jaundice, Biliary Atresia & Choledochal Cyst, Hepatitis, Food Allergy, and Kerosene, Aspirin and INH Poisoning

28 Chapter 28: Pediatrics III: Genitourinary, Endocrine, Hematologic & Oncologic Disorders

28.1 Pediatric Genitourinary Disorders & Child Abuse: UTI and Vesicoureteral Reflux, Post-Streptococcal GN and Other Nephritides, Nephrotic Syndrome, AKI and HUS, CKD, Congenital Urogenital Anomalies, and Recognizing and Reporting Child Abuse 28.2 Pediatric Endocrine & Metabolic Disorders: Short Stature and Growth Hormone, Gigantism, Diabetes Insipidus, Congenital Hypothyroidism, Graves Disease & Goiter, Type 1 Diabetes and DKA, Congenital Adrenal Hyperplasia, Cushing Syndrome, Pheochromocytoma and Adrenal Crisis 28.3 Pediatric Hematology, Allergy & Immunology: Normal Hemogram and Immunoglobulins by Age, Anemias (Iron Deficiency, Thalassemia, G6PD, Spherocytosis, Aplastic), Bleeding Disorders (ITP, Hemophilia, vWD, DIC, Vitamin K), IgA Vasculitis, Rashes and Drug Reactions, Asthma, Allergic Rhinitis and Primary Immunodeficiencies 28.4 Pediatric Oncology & Genetics: Leukemias and Lymphomas, Retinoblastoma, Wilms Tumor, Neuroblastoma, Ewing Sarcoma and Osteosarcoma; Sex Chromosome and Autosomal Disorders, Inborn Errors of Metabolism and the Dysmorphic ("Odd-Looking") Child

29 Chapter 29: Preventive Medicine I: The Physician as Health Care Provider

29.1 The Physician as Health Care Provider I: Natural History of Disease, Disease Causation, Levels of Prevention and Primary Care Across the Clinical Rotations 29.2 The Physician as Health Care Provider II: The Filipino Family and Family Assessment Tools, Health Education and Promotion, Behavior Change Models and Geriatric Medicine 29.3 The Physician as Health Care Provider III: The Primary Health Care Concept (Alma-Ata, Astana, Philippine PHC) and Mental Health in Primary Care under RA 11036

30 Chapter 30: Preventive Medicine II: Philippine Health Care System & Community Medicine

30.1 The Philippine Health Care System: DOH Structure, Levels of Care and Referral, Devolution under RA 7160, the Universal Health Care Act (RA 11223), PhilHealth and YAKAP, and Leading Causes of Morbidity and Mortality 30.2 Epidemiology, Surveillance & Outbreaks: Measures of Disease Occurrence and Association, Rates, Endemic and Epidemic Levels, PIDSR and RA 11332 Notifiable Diseases, the Ten Steps of Outbreak Investigation and Epidemic Curves 30.3 DOH Programs & Environmental Sanitation: TB, Dengue, Rabies, Leprosy, Helminth and Other Disease Programs; the Sanitation Code (PD 856), Water Supply and Potability, Excreta and Solid Waste, Food Sanitation and Health Care Waste 30.4 Community Medicine: Principles of Public Health Administration and Program Planning, Vital Health Indices (Infant and Maternal Mortality), the Ecologic Concept of Health, Lifestyle and Non-Communicable Diseases, Health-Seeking Behavior and Traditional Medicine

31 Chapter 31: Preventive Medicine III: Manager, Researcher & Social Mobilizer

31.1 The Physician as Administrative Manager: Communication and Interpersonal Skills, Teamwork, Adult Learning, Occupational Health (RA 11058), Bioethics, Palliative Care, School Health, Organ Transplantation and Birth and Death Certificates 31.2 The Physician as Researcher I: The Research Process and Proposal, Research Ethics, Study Designs and Meta-Analysis, Demography and Vital Statistics, Evidence-Based Medicine and Quality Assurance 31.3 The Physician as Researcher II: Biostatistics (Data Types, Distributions, Central Tendency and Dispersion, Confidence Intervals, Hypothesis Testing and Test Selection) and Screening Tests (Validity, Predictive Values, Likelihood Ratios, Biases and Program Criteria) 31.4 The Physician as Social Mobilizer and Leader: Philippine Health Laws, Decrees and Executive Orders, Principles of Social Mobilization and Community Organizing, and Disaster Risk Reduction and Management in Health

32 Chapter 32: Pharmacology I: Principles, Cardiovascular & Nervous System Therapeutics

32.1 Pharmacology Foundations: The Pharmacology TOS, Pharmacokinetics, Drug Metabolism and Interactions, Pharmacodynamics, Adverse Drug Reactions and Monitoring, Autonomic Pharmacology, and Philippine Prescribing Rules 32.2 Cardiovascular Pharmacology I: Cardiac Arrest and ACLS Drugs, Bradycardia and Complete Heart Block, Antiarrhythmics, Anticoagulation in Atrial Fibrillation, Antianginals, ACS Therapy and Fibrinolysis, Pericarditis and Endocarditis Regimens 32.3 Cardiovascular Pharmacology II: Antihypertensives and Diuretics, Hypertensive Emergencies, Vasopressors and Inotropes in Shock, Heart Failure GDMT and Digoxin, and Lipid-Lowering Therapy 32.4 Nervous System Pharmacology I: Antiseizure Drugs and Status Epilepticus, Headache and Migraine, Vertigo, Stroke Thrombolysis and Secondary Prevention, Encephalopathy, Dementia, ADHD, Parkinson Disease and Movement Disorders, Raised Intracranial Pressure and CNS Infections

33 Chapter 33: Pharmacology II: Psychiatric, Respiratory & Genitourinary Therapeutics

33.1 Nervous System Pharmacology II: Antidepressants and Their Toxicity, Serotonin Syndrome, Anxiolytics and Hypnotics, Antipsychotics, EPS and NMS, Lithium and Mood Stabilizers, Sleep Disorders, Agitation and Alcohol Withdrawal 33.2 Respiratory Pharmacology: Cough and Colds, Allergic Rhinitis, Asthma (Controllers, Relievers, Exacerbations), COPD, Anti-TB Drugs, Antibiotics for Pneumonia and Bronchitis, and Lung Cancer Therapy 33.3 Genitourinary Pharmacology I: Antimicrobial Classes and Toxicities, and Drug Treatment of UTI, Pyelonephritis, Gonorrhea, Chlamydia, Syphilis, Genital Herpes, Genital Warts, PID, Vaginitis, Prostatitis and Orchitis 33.4 Genitourinary Pharmacology II: Kidney Stones, Nephrotic and Nephritic Disease, Drug Dosing in Kidney Disease and Hyperkalemia, Benign Prostatic Hyperplasia, Erectile Dysfunction, Renal Cell Carcinoma and Prostate Cancer Therapy

34 Chapter 34: Pharmacology III: Digestive, Endocrine, Skin & Musculoskeletal Therapeutics

34.1 Digestive Pharmacology: Portal Hypertension and Variceal Bleeding, Acid-Peptic Disease, H. pylori and GERD, Antiemetics, Laxatives and Antidiarrheals, Biliary and Pancreatic Disease, GI Infections and Parasites, Viral Hepatitis, C. difficile, Candidiasis and GI Cancer Chemotherapy 34.2 Endocrine Pharmacology I: Diabetes Mellitus Drugs (Metformin, Sulfonylureas, SGLT2 Inhibitors, GLP-1 Agonists, DPP-4 Inhibitors, Thiazolidinediones, Insulins), Choosing Therapy by Comorbidity, DKA and HHS, and Hypoglycemia 34.3 Endocrine Pharmacology II: Pituitary Disorders (GH Deficiency, Acromegaly, Prolactinoma, Diabetes Insipidus, Panhypopituitarism), Thyroid Drugs and Thyroid Storm, Calcium and Parathyroid Disorders, Adrenal Disorders and Corticosteroids 34.4 Cutaneous and Musculoskeletal Pharmacology: Cellulitis and Abscess, Drug-Induced Skin Reactions (SJS/TEN), Pain Management (Paracetamol, NSAIDs, Opioids), Osteoporosis, Rheumatoid Arthritis and Osteoarthritis, Septic and TB Arthritis, Gout, SLE and Psoriasis

35 Chapter 35: Surgery I: Basic Surgical Principles

35.1 Basic Surgical Principles I: The Surgery TOS, Fluids and Electrolytes, Acid-Base Balance, the Metabolic Response to Injury, Surgical Nutrition and Blood Transfusion 35.2 Basic Surgical Principles II: Shock and Surgical Critical Care, Hemorrhagic Shock and Massive Transfusion, ATLS Primary and Secondary Survey, Chest and Abdominal Trauma, Head and Spine Injury, Pelvic Fractures and Burns 35.3 Basic Surgical Principles III: Preoperative Assessment, Wound Healing, Surgical Infection and Asepsis, Postoperative Fever, Surgical Oncology, Immunology and Transplantation, Anesthesia and Patient Safety

36 Chapter 36: Surgery II: Abdomen, Breast & Hernia

36.1 Abdomen I: Esophagus (Hiatal Hernia, GERD, Achalasia, Caustic Injury, Barrett, Boerhaave, Mallory-Weiss, Cancer), Stomach and Duodenum (Peptic Ulcer Complications, Upper GI Bleeding, Gastric Cancer, GIST), Small Bowel (Obstruction, Ileus, Tumors, Typhoid and TB), Retroperitoneum and Abdominal Wall 36.2 Abdomen II: Gallstones, Cholecystitis, Choledocholithiasis and Cholangitis, Obstructive Jaundice, Liver (Cirrhosis, Portal Hypertension, Abscesses, Tumors and Hepatocellular Carcinoma), Pancreas (Acute and Chronic Pancreatitis, Pancreatic Cancer) and Spleen (Splenectomy, OPSI) 36.3 Abdomen III: Acute Appendicitis, Colonic Obstruction and Volvulus, Lower GI Bleeding, Diverticular Disease, Colorectal Polyps and Cancer, Hemorrhoids, Anal Fissure, Perianal Abscess and Fistula 36.4 Breast, Hernia and Skin and Soft Tissue: Benign Breast Masses, Breast Cancer Evaluation and Treatment, Groin and Abdominal Wall Hernias, Benign Skin and Soft-Tissue Tumors, Skin Cancers and Soft-Tissue Sarcoma

37 Chapter 37: Surgery III: Surgical Specialties

37.1 Head and Neck, Thyroid, Parathyroid, Endocrine and Bariatric Surgery and Otorhinolaryngology: Neck Masses and Head and Neck Cancer, Salivary Glands, Thyroid Nodules and Cancer, Goiter and Hyperthyroidism Surgery, Hyperparathyroidism, Adrenal Surgery, Bariatric Surgery, Nasal Polyps, Epistaxis, Vertigo, Hearing Loss and ENT Infections 37.2 Specialty I: Neurosurgery (Raised Intracranial Pressure and Herniation, Head Injury and Hematomas, Spontaneous Intracranial Hemorrhage, CNS and Peripheral Nerve Tumors, Spinal Cord Compression, Neurosurgical Infections) and Ophthalmology (Glaucoma, Cataract, Ophthalmic Emergencies) 37.3 Specialty II: Thoracic and Cardiovascular Surgery (Pleural Effusion and Empyema, Lung Cancer, Mediastinal Masses, Surgical Heart Disease, Aortic Aneurysm and Dissection, Peripheral Arterial and Venous Disease), Urology (Stones, Infections, Torsion, BPH, Urologic Tumors) and Gynecologic Surgery 37.4 Specialty III: Plastic and Reconstructive Surgery (Skin Grafts and Flaps, Cleft Lip and Palate, Facial Fractures, Hand Injuries), Orthopedics (Fractures, Dislocations, Bone and Joint Infections, Bone Tumors) and Pediatric Surgery (Hernias, CDH, Esophageal Atresia, Obstruction, Hirschsprung Disease, Neonatal Jaundice, Tumors)

38 Chapter 38: Medicine I: Cardiovascular, Digestive & Endocrine Medicine

38.1 Cardiovascular Medicine I: Hypertension and Secondary Causes, Dyslipidemia, Stable Angina and Acute Coronary Syndromes, Post-MI Complications, Heart Failure and Shock Syndromes 38.2 Cardiovascular Medicine II: Tachyarrhythmias and Bradyarrhythmias, Atrial Fibrillation, Sudden Cardiac Death and Brugada Syndrome, Cardiac Arrest, Valvular and Rheumatic Heart Disease, Infective Endocarditis, Myocarditis and Pericardial Disease 38.3 Gastroenterology and Hepatology: GERD and Peptic Ulcer Disease, Upper and Lower GI Bleeding, Diarrhea and GI Infections, Acute Pancreatitis and Biliary Disease, Viral Hepatitis, Cirrhosis and Portal Hypertension, Liver and GI Cancers 38.4 Endocrinology: Diabetes Mellitus Diagnosis, Treatment and Complications, DKA and HHS, Thyroid Disease, Pituitary Disorders, Adrenal Disorders (Cushing, Aldosteronism, Addison, Pheochromocytoma), Calcium and Parathyroid Disorders, Obesity and Metabolic Syndrome

39 Chapter 39: Medicine II: Hematology, Systemic Infections, Renal & Respiratory Medicine

39.1 Hematology, Immunology and Systemic Infections: Anemias (Iron Deficiency, Thalassemia, G6PD Deficiency, Megaloblastic, Hemolytic), Acute and Chronic Leukemias and Their Emergencies, Allergic Disorders, Dengue in Adults, COVID-19, Malaria and HIV/AIDS Opportunistic Infections 39.2 Nephrology: Acute Kidney Injury, Chronic Kidney Disease and Dialysis, Sodium and Potassium Disorders, Acid-Base Analysis, Urinary Tract Infections, Glomerular Diseases (Nephritic and Nephrotic), Kidney Stones, Renal Tumors and Sexually Transmitted Infections 39.3 Pulmonology and Critical Care: Acute Respiratory Failure and Oxygen Therapy, Bronchial Asthma, COPD, Community- and Hospital-Acquired Pneumonia, Pulmonary Tuberculosis and TB Infection, Pulmonary Embolism, Lung Cancer and ARDS

40 Chapter 40: Medicine III: Rheumatology, Dermatology, Neurology, Rehabilitation & Psychiatry

40.1 Rheumatology and Dermatology: Approach to Arthritis, Osteoarthritis, Rheumatoid Arthritis, Gout, Spondyloarthritis, SLE and Other Connective Tissue Diseases, Vasculitis and Myalgias, Bone Tumors, Common Skin Lesions, Skin Infections and Infestations, Eczema, Psoriasis, Severe Drug Eruptions and Skin Signs of Systemic Disease 40.2 Neurology and Rehabilitation Medicine: Stroke and TIA (Localization, Thrombolysis, Thrombectomy, Secondary Prevention), Intracranial Hemorrhage, Seizures and Status Epilepticus, Meningitis and Encephalitis, Tetanus and Rabies, Parkinsonism, Neuromuscular and Degenerative Diseases, Dementia, CNS Tumors, Post-Stroke Rehabilitation and Musculoskeletal Disorders 40.3 Psychiatry: Mental Status Examination, Depressive Disorders, Bipolar Disorder, Schizophrenia and Other Psychoses, Anxiety Disorders, OCD and Trauma-Related Disorders, Substance Use, and Acute Psychiatric Emergencies (Suicide Risk, Agitation, Withdrawal, Wernicke Encephalopathy)

23.2 Hypertension & Diabetes in Pregnancy: Classification, Preeclampsia Pathogenesis and Prevention, Severe Features, Eclampsia & HELLP, Magnesium Sulfate, Gestational and Pregestational Diabetes

Key Takeaways Explain This Topic AI

Preeclampsia is new hypertension at or after 20 weeks with proteinuria or end-organ dysfunction; severe features include BP of 160/110 or more, platelets below 100,000, doubled transaminases, creatinine above 1.1, pulmonary edema and cerebral or visual symptoms.

Low-dose aspirin started at 12 to 16 weeks (before 16 weeks) and continued to 36 weeks reduces preeclampsia in high-risk women.

Acute severe hypertension (160/110 or more for 15 minutes) is treated within 30 to 60 minutes with IV labetalol, IV hydralazine or oral immediate-release nifedipine.

Preeclampsia with severe features is delivered at 34 weeks or once stabilized if beyond that; gestational hypertension and preeclampsia without severe features are delivered at 37 weeks.

Women with gestational diabetes need a 75 g OGTT 4 to 12 weeks postpartum and lifelong diabetes screening, because about half develop type 2 diabetes later.

Last updated: October 2026

Why this area matters

TOS areas F and G ask you to:

  • classify hypertensive disorders and their risk factors;
  • differentiate their signs and severity;
  • manage hypertension and its complications;
  • screen early;
  • manage diabetes in pregnancy and its fetal and maternal complications;

prevent recurrence and protect long-term health.

Hypertensive disorders, especially eclampsia, are a leading cause of maternal death in the Philippines. Many eclampsia deaths follow missed blood pressure checks, unrecognized severe features or delayed magnesium sulfate. Gestational diabetes is rising with obesity in Filipino women and predicts later type 2 diabetes.

Pathogenesis and prevention of preeclampsia

Pathogenesis:

  • in normal pregnancy, trophoblast invades and remodels the spiral arteries into wide, low-resistance vessels;
  • in preeclampsia, this remodeling is shallow and incomplete , so the placenta becomes ischemic;

the ischemic placenta releases antiangiogenic factors ( soluble fms-like tyrosine kinase-1, sFlt-1 , and soluble endoglin) and less placental growth factor (PlGF) ;

the result is widespread endothelial dysfunction : vasoconstriction, capillary leak, glomerular endotheliosis, platelet activation and microangiopathy.

Risk factors:

high-risk: previous preeclampsia, chronic hypertension, pregestational diabetes, renal disease, autoimmune disease (SLE, antiphospholipid syndrome) and multiple gestation;

moderate-risk: nulliparity, obesity, age 35 or more, family history, a long interpregnancy interval and in vitro fertilization.

Prevention:

low-dose aspirin (81 mg daily in ACOG guidance, 150 mg at night in FIGO and other guidance), started at 12 to 16 weeks, ideally before 16 weeks , and continued until 36 weeks, for women with one high-risk factor or more than one moderate-risk factor;

calcium supplementation for women with low dietary calcium.

Screening: check blood pressure and urine protein at every antenatal visit, and teach the danger signs: headache, visual disturbance, epigastric pain and edema of the face and hands.

Hypertensive Disorders of Pregnancy

Hypertensive diseases complicating pregnancy are classified into four major categories based on gestational age of onset, proteinuria, and multisystem end-organ compromise.

Diagnostic Classification

Chronic Hypertension: Hypertension (systolic BP ≥ 140 mmHg \ge 140\text{ mmHg} ≥ 140 mmHg or diastolic BP ≥ 90 mmHg \ge 90\text{ mmHg} ≥ 90 mmHg ) that precedes pregnancy, is diagnosed before 20 weeks of gestation, or persists beyond 12 weeks postpartum.

Gestational Hypertension: New-onset systolic BP ≥ 140 mmHg \ge 140\text{ mmHg} ≥ 140 mmHg or diastolic BP ≥ 90 mmHg \ge 90\text{ mmHg} ≥ 90 mmHg diagnosed at or after 20 weeks of gestation in the absence of proteinuria or systemic end-organ signs. Blood pressure normalizes within 12 weeks postpartum.

Preeclampsia without Severe Features: New-onset hypertension (BP ≥ 140 / 90 mmHg \ge 140/90\text{ mmHg} ≥ 140/90 mmHg on two occasions at least 4 hours apart) occurring at ≥ 20 \ge 20 ≥ 20 weeks of gestation in a previously normotensive woman, accompanied by proteinuria :

  • ≥ 300 mg \ge 300\text{ mg} ≥ 300 mg per 24-hour urine collection, OR
  • Urine protein-to-creatinine ratio (UPCR) ≥ 0.3 mg/mg \ge 0.3\text{ mg/mg} ≥ 0.3 mg/mg , OR

Urine dipstick reading of 2 + 2+ 2 + (used only if quantitative methods are unavailable).

Preeclampsia with Severe Features (PE with SF): Diagnosed in the presence of preeclampsia when ANY of the following severe features are identified (even in the absence of proteinuria):

Severe Hypertension: Systolic BP ≥ 160 mmHg \ge 160\text{ mmHg} ≥ 160 mmHg or diastolic BP ≥ 110 mmHg \ge 110\text{ mmHg} ≥ 110 mmHg on two occasions at least 4 hours apart (confirmation within minutes is enough if antihypertensive therapy has to be started sooner).

Thrombocytopenia: Platelet count < 100 , 000 / μ L < 100,000/\mu\text{L} < 100 , 000/ μ L .

Impaired Liver Function: Serum transaminases (AST or ALT) elevated to at least twice the upper limit of normal, or persistent severe right upper quadrant or epigastric pain unresponsive to medication and not accounted for by alternative diagnoses.

Renal Insufficiency: Serum creatinine > 1.1 mg/dL > 1.1\text{ mg/dL} > 1.1 mg/dL or a doubling of serum creatinine in the absence of pre-existing renal disease.

Pulmonary Edema.

New-onset Cerebral or Visual Disturbances: Severe persistent headache refractory to analgesics, scotomata, photopsia, blurred vision, or altered mental status.

Eclampsia: The occurrence of new-onset grand mal (generalized tonic-clonic) seizures in a woman with preeclampsia that cannot be attributed to other neurologic conditions (such as epilepsy, intracerebral hemorrhage, or meningitis).

HELLP Syndrome: A severe variant of preeclampsia defined by:

H (Hemolysis): Microangiopathic hemolytic anemia with schistocytes on peripheral smear, elevated total bilirubin ≥ 1.2 mg/dL \ge 1.2\text{ mg/dL} ≥ 1.2 mg/dL , and serum lactate dehydrogenase (LDH) > 600 U/L > 600\text{ U/L} > 600 U/L .

EL (Elevated Liver enzymes): Serum AST or ALT ≥ 2 × \ge 2\times ≥ 2 × upper limit of normal.

LP (Low Platelets): Platelet count < 100 , 000 / μ L < 100,000/\mu\text{L} < 100 , 000/ μ L . Complications include hepatic subcapsular hematoma, hepatic rupture, and DIC.

Classification Onset Timing Proteinuria Severe Features Distinguishing Criteria

Chronic Hypertension Before pregnancy or < 20 <20 < 20 weeks Absent (unless baseline nephropathy) Absent Persists > 12 >12 > 12 weeks postpartum

Gestational Hypertension At or after 20 weeks Absent Absent Normalizes by 12 weeks postpartum

Preeclampsia without SF At or after 20 weeks Present ( ≥ 300 mg / 24 h \ge 300\text{ mg}/24\text{h} ≥ 300 mg /24 h ) Absent BP 140-159 / 90-109 mmHg; no end-organ signs

Preeclampsia with SF At or after 20 weeks Present or Absent Present BP ≥ 160 / 110 \ge 160/110 ≥ 160/110 , Plt < 100 k <100k < 100 k , AST/ALT 2x, Cr > 1.1 >1.1 > 1.1 , Pulm edema, Neuro

Eclampsia Antepartum, Intrapartum, Postpartum Present or Absent Seizures Generalized tonic-clonic convulsions

HELLP Syndrome Mid-to-late pregnancy / postpartum Present or Absent Microangiopathy Hemolysis (LDH > 600 >600 > 600 ), AST ≥ 2 × \ge 2\times ≥ 2 × , Platelets < 100 , 000 / μ L <100,000/\mu\text{L} < 100 , 000/ μ L

Medical Management of Severe Preeclampsia and Eclampsia

Definitive treatment of preeclampsia is delivery of the fetus and placenta. Medical stabilization with antihypertensive therapy and seizure prophylaxis must occur prior to delivery.

Acute Antihypertensive Therapy for Severe Hypertension (BP ≥ 160 / 110 mmHg \ge 160/110\text{ mmHg} ≥ 160/110 mmHg )

The goal of therapy is to lower blood pressure into the safe range (systolic 140-150 mmHg, diastolic 90-100 mmHg) to prevent maternal stroke and abruption while preserving uteroplacental perfusion:

IV Labetalol (Combined α / β \alpha/\beta α / β -blocker): First-line agent. Initial dose 20 mg IV bolus over 2 minutes. If BP remains ≥ 160 / 110 mmHg \ge 160/110\text{ mmHg} ≥ 160/110 mmHg after 10 to 20 minutes, administer 40 mg, then 80 mg every 10 to 20 minutes to a maximum cumulative dose of 220 mg. Contraindicated in maternal asthma, severe sinus bradycardia, or uncompensated heart failure.

IV Hydralazine (Direct arteriolar vasodilator): Initial dose 5 to 10 mg IV bolus over 2 minutes. Repeat with 5 to 10 mg IV after 20 to 30 minutes if needed (maximum cumulative dose 20-30 mg). Risk of reflex tachycardia and precipitous maternal hypotension.

Oral Nifedipine (Immediate-release dihydropyridine calcium channel blocker): 10 to 20 mg orally (swallowed, never administered sublingually due to risk of sudden fatal hypotension). Repeat in 20 minutes if needed, then 10 to 20 mg every 2 to 6 hours.

Strict Contraindication: Angiotensin-Converting Enzyme Inhibitors (ACEi) and Angiotensin Receptor Blockers (ARBs) are teratogenic and fetotoxic (causing oligohydramnios, fetal renal dysgenesis, skull hypoplasia, and neonatal death).

Magnesium Sulfate ( MgSO 4 \text{MgSO}_4 MgSO 4 ​ ) Seizure Prophylaxis

Magnesium sulfate is the drug of choice for preventing eclamptic convulsions in preeclampsia with severe features and for arresting active eclamptic seizures (superior to phenytoin and diazepam). It acts as a central NMDA receptor antagonist and cerebral vasodilator.

Administration Regimens:

Zuspan Intravenous Regimen: Loading dose of 4 g IV in 100 mL D 5 W D_5W D 5 ​ W infused over 15 to 20 minutes, followed by a continuous maintenance infusion of 1 to 2 g/hour IV.

Pritchard Intramuscular Regimen: Loading dose of 4 g IV plus 10 g deep IM (5 g in each buttock with 1 mL 2% lidocaine), followed by 5 g IM in alternating buttocks every 4 hours.

Monitoring for Hypermagnesemic Toxicity: Magnesium is excreted exclusively by the kidneys. Clinical monitoring must be performed every hour:

Patellar Reflexes (Deep Tendon Reflexes): The therapeutic serum level is about 4 to 7 mEq/L (4.8 to 8.4 mg/dL) . Loss of patellar reflexes is the earliest clinical sign of toxicity , appearing at about 7 to 10 mEq/L.

Respiratory Rate: Respiratory depression ( < 12 breaths/min < 12\text{ breaths/min} < 12 breaths/min ) and then respiratory paralysis appear at about 10 to 13 mEq/L.

Urine Output: Must remain ≥ 30 mL/hr \ge 30\text{ mL/hr} ≥ 30 mL/hr (or ≥ 100 mL/4 hours \ge 100\text{ mL/4 hours} ≥ 100 mL/4 hours ). If oliguria develops, magnesium rapidly accumulates, precipitating toxicity.

Cardiac Toxicity: Conduction changes appear above about 15 mEq/L, and cardiac arrest at about 25 mEq/L or more.

Antidote for Toxicity: Immediately discontinue the MgSO 4 \text{MgSO}_4 MgSO 4 ​ infusion. Administer 10 mL of 10% Calcium Gluconate (1.0 g) IV push slowly over 3 to 5 minutes.

Further points on hypertensive disorders:

Treat urgently: severe-range BP of 160/110 or more that persists for 15 minutes must be treated within 30 to 60 minutes to prevent stroke.

Chronic hypertension: keep BP below 140/90 . Use labetalol, nifedipine or methyldopa, and avoid ACE inhibitors and ARBs.

Managing an eclamptic seizure:

  • protect the airway;
  • turn the patient to the left side;
  • give oxygen;
  • give magnesium sulfate (not diazepam);
  • control blood pressure;

deliver once she is stable.

Recurrent seizures: give a further 2 g of magnesium sulfate IV.

Postpartum: continue magnesium sulfate for 24 hours after delivery or after the last seizure . Preeclampsia and eclampsia can first appear up to 6 weeks postpartum .

Timing of delivery:

gestational hypertension or preeclampsia without severe features: at 37 weeks ;

preeclampsia with severe features: at 34 weeks or after maternal stabilization (with steroids if preterm). Deliver at once for eclampsia, HELLP with complications, pulmonary edema, abruption or a nonreassuring fetal status.

Preeclampsia itself is not an indication for cesarean.

Long-term risk: women with preeclampsia have a higher lifelong risk of chronic hypertension, ischemic heart disease and stroke, so their BP and cardiovascular risk should be monitored after pregnancy.

Gestational Diabetes Mellitus (GDM)

Gestational diabetes is carbohydrate intolerance resulting in hyperglycemia with onset or first recognition during pregnancy.

Pathophysiology: Placental secretion of diabetogenic hormones—primarily Human Placental Lactogen (hPL) , along with progesterone, cortisol, and prolactin—induces maternal peripheral insulin resistance starting in the late second trimester. This spares glucose for transplacental transfer to the fetus. In GDM, maternal pancreatic β \beta β -cells fail to mount a compensatory hyperinsulinemic response.

Diagnostic Screening: Administered universally between 24 and 28 weeks of gestation using the IADPSG / WHO One-Step 75-gram Oral Glucose Tolerance Test (OGTT) :

Fasting plasma glucose: ≥ 92 mg/dL \ge 92\text{ mg/dL} ≥ 92 mg/dL ( 5.1 mmol/L 5.1\text{ mmol/L} 5.1 mmol/L )

1-hour plasma glucose: ≥ 180 mg/dL \ge 180\text{ mg/dL} ≥ 180 mg/dL ( 10.0 mmol/L 10.0\text{ mmol/L} 10.0 mmol/L )

2-hour plasma glucose: ≥ 153 mg/dL \ge 153\text{ mg/dL} ≥ 153 mg/dL ( 8.5 mmol/L 8.5\text{ mmol/L} 8.5 mmol/L )

A single abnormal value establishes the diagnosis of GDM.

Maternal and Fetal Risks:

Fetal Complications: Maternal hyperglycemia triggers fetal hyperglycemia and subsequent fetal hyperinsulinemia (Pedersen hypothesis). Insulin acts as a major fetal anabolic hormone, driving fetal macrosomia (birth weight > 4 , 000 g > 4,000\text{ g} > 4 , 000 g or > 4 , 500 g > 4,500\text{ g} > 4 , 500 g ), asymmetric septal cardiac hypertrophy, polyhydramnios, and organomegaly. Neonatal risks include birth trauma (shoulder dystocia, clavicular fracture, Erb's palsy), neonatal hypoglycemia (abrupt cessation of maternal glucose supply while fetal hyperinsulinemia persists after cord clamping), hypocalcemia, polycythemia, hyperbilirubinemia, and Neonatal Respiratory Distress Syndrome (hyperinsulinism impairs surfactant production by inhibiting type II pneumocyte maturation).

Absence of Structural Congenital Anomalies: Isolated GDM develops during the second and third trimesters after organogenesis is complete, and thus does NOT increase the risk of congenital structural anomalies (unlike pregestational diabetes, which is linked to caudal regression syndrome and ventricular septal defects).

Management: First-line therapy is Medical Nutrition Therapy (MNT) and moderate physical activity. If fasting glucose remains ≥ 95 mg/dL \ge 95\text{ mg/dL} ≥ 95 mg/dL or 2-hour postprandial glucose remains ≥ 120 mg/dL \ge 120\text{ mg/dL} ≥ 120 mg/dL , pharmacotherapy is initiated with Insulin (the gold standard, as it does not cross the placenta).

Pregestational diabetes and long-term follow-up

Preconception care:

aim for HbA1c below 6.5% before conception, because high glucose during organogenesis causes anomalies and miscarriage;

give folic acid;

screen for retinopathy and nephropathy.

Anomalies of pregestational diabetes:

  • cardiac defects (transposition of the great arteries, VSD);
  • neural tube defects;
  • renal anomalies;

caudal regression syndrome , rare but characteristic.

Other risks:

  • stillbirth;
  • polyhydramnios;
  • preeclampsia;
  • diabetic ketoacidosis , which develops at lower glucose levels in pregnancy;

worsening retinopathy.

Insulin is the preferred drug. Requirements rise through pregnancy, then fall sharply after the placenta is delivered .

Labor and delivery:

  • control glucose during labor to prevent neonatal hypoglycemia ;
  • feed the newborn early and check glucose;

watch for hypocalcemia, polycythemia, jaundice and respiratory distress.

Timing of delivery: well-controlled gestational diabetes on diet alone is delivered at about 39 to 40 weeks. Medication-treated or pregestational diabetes is usually delivered at 39 weeks, or earlier if control is poor or there are complications.

After gestational diabetes:

  • stop insulin and check glucose;
  • do a 75 g OGTT at 4 to 12 weeks postpartum ;

screen for diabetes every 1 to 3 years for life, because about half of women develop type 2 diabetes within a decade or two;

encourage breastfeeding , weight control and exercise, which lower this risk;

screen early in the next pregnancy.

Loading diagram... Diagnostic Spectrum and Stratification of Hypertensive Disorders of Pregnancy